On August 1, 2019 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, reported that it will participate in the following investor conferences in August (Press release, Audentes Therapeutics, AUG 1, 2019, View Source [SID1234538033]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
SVB Leerink Spotlight Series on Rare & Genetic Diseases
Natalie Holles, President and Chief Operating Officer
Format: Fireside Chat
Thursday, August 8, 2019, at 10:00 am ET
Boston, Massachusetts
2019 Wedbush PacGrow Healthcare Conference
Matthew R. Patterson, Chairman and Chief Executive Officer
Format: Corporate Presentation
Wednesday, August 14, 2019, at 10:20 am ET
New York, New York
To access the live webcast of the Wedbush presentation, please visit the Events & Presentations page within the Investors + Media section of the Audentes website. Following the Wedbush conference, a replay of the live webcast will be available on the Audentes website for approximately 30 days. There is no webcast available for the fireside chat at the SVB Leerink Spotlight Series on Rare & Genetic Diseases Conference.
About Audentes Therapeutics, Inc.
Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Our product candidates are showing promising therapeutic profiles in clinical and preclinical studies